<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03222453</url>
  </required_header>
  <id_info>
    <org_study_id>201508020258</org_study_id>
    <nct_id>NCT03222453</nct_id>
  </id_info>
  <brief_title>Thalassemia Treatment Based on the Stem Cell Technology</brief_title>
  <official_title>The Third Affiliated Hospital of Guangzhou Medical University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiaofang Sun</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Third Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to study the transplantation effect of hematopoetic stem cells from beta-thalassemia&#xD;
      induced pluripotent stem cells. We applied clinical grade source of autologous hematopoietic&#xD;
      stem cell for the treatment of beta-thalassemia patients, detecting the homing of&#xD;
      hematopoietic stem cell transplantation, the differentiation of hematopoietic stem cells in&#xD;
      vivo and the hemoglobin beta-chain (HBB) protein expression in the body of recovery, etc., as&#xD;
      well as to make a research on the efficacy and safety of hematopoietic stem cells from&#xD;
      beta-thalassemia induced pluripotent stem cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. On a Good Manufacturing Practice(GMP) condition, we establish non-exotic of different&#xD;
           mutation types of beta-thalassemia -induced pluripotent stem cells（iPS） and make a&#xD;
           comparisons of the stability and the differentiation of efficiency of these iPS cells&#xD;
           inducing from different sources with foreign gene integration.&#xD;
&#xD;
        2. Using the technique of artificial nuclease and in situ repairmen, we establish efficient&#xD;
           system for different beta-thalassemia mutation site and in view of the security of these&#xD;
           system.&#xD;
&#xD;
        3. Establish a repaired beta-thalasemia gene mutated differentiation of iPS technology&#xD;
           system.&#xD;
&#xD;
        4. Build a functional gene therapy self-limiting slow viruses, optimizing the preparation&#xD;
           system and to establish a virus preparation of infection of hematopoietic stem cell&#xD;
           technology system under the GMP condition.&#xD;
&#xD;
        5. Establish humanized beta-mice model, evaluate the safety of the iPS cell of gene therapy&#xD;
           and efficiency before the clinical experiment.&#xD;
&#xD;
        6. Improve the existing hematopoietic stem cell transplant(HSCT) clinical application&#xD;
           solutions, detect rate of graft rejection, rate of transplantation and other indicators,&#xD;
           finish the evaluation of application by clinical cases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">June 14, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The check of granulocyte transplantation-granulocyte plant living standards</measure>
    <time_frame>3 days</time_frame>
    <description>Granulocyte plant living standards for three days in a row after transplantation granulocyte should be greater than 0.5 x 109 / L,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The check of granulocyte transplantation-platelet plant living standards</measure>
    <time_frame>seven consecutive days</time_frame>
    <description>Platelet plant living standard for seven consecutive days after transplantation the platelet should be greater than 20 x 109 / L and infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of cell transplantation</measure>
    <time_frame>seven days</time_frame>
    <description>The granulocyte plant living standards and platelet plant living standards will be combined to measure the effect of cell transplantation.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Beta-Thalassemia</condition>
  <arm_group>
    <arm_group_label>Intervention Patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-intervention Patient</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoetic stem cells</intervention_name>
    <description>Patient will inject with hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells</description>
    <arm_group_label>Intervention Patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The genetic diagnosis confirmed homozygous for beta to poverty or double heterozygote,&#xD;
             clinical severe anemia;&#xD;
&#xD;
          2. Aged 1 ~ 18 years old, no obvious iron overload cause organ damage;&#xD;
&#xD;
          3. Has a suitable donor HLA high resolution;&#xD;
&#xD;
          4. The informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. There has been a significant increase in the level of tumor markers (AFP/CEA/CA199 /&#xD;
             CA125) in the past five years.&#xD;
&#xD;
          2. Serious primary diseases such as cardiovascular, liver and hematopoietic systems;&#xD;
             Those who have major organs with serious function; An adrenal disease or other disease&#xD;
             that causes the organ failure of the organ;&#xD;
&#xD;
          3. An autoimmune disease, a family history of genetic disease, and an abnormal thyroid&#xD;
             function;&#xD;
&#xD;
          4. Peripheral blood chromosome checking for nuclear aliens;&#xD;
&#xD;
          5. HIV, hepatitis b or hepatitis c;&#xD;
&#xD;
          6. A person with a history of severe drug allergies or an allergic person;&#xD;
&#xD;
          7. Those who do not expect to live for more than one year;&#xD;
&#xD;
          8. The researchers suggest that the patient may have a potential or have a disorder (such&#xD;
             as an uncontrolled infection, right heart failure, pulmonary hypertension) that is&#xD;
             interfering with this study.&#xD;
&#xD;
          9. In the first six months, alcohol and other substance abuse were not allowed;&#xD;
&#xD;
         10. Subjects who participated in other clinical trials or participated in other clinical&#xD;
             trials within 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Clinical diagnosis.</gender_description>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>July 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2017</study_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Third Affiliated Hospital of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Xiaofang Sun</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>thalassemia</keyword>
  <keyword>stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 3, 2018</submitted>
    <returned>November 30, 2018</returned>
    <submitted>September 23, 2019</submitted>
    <returned>October 16, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

